

• **Name:** Myung Ah Lee

• **Current Position:**

Chief of Medical Oncology, Seoul St. Mary's hospital, Catholic University

Director of Colorectal cancer center, Seoul St. Mary's hospital Comprehensive Cancer Center,
The Catholic University University

Chief of IRB panel V, Seoul St. Mary's hospital, Catholic University

Head of evaluation department, Seoul St. Mary's hospital, Catholic University

• **Country:** South Korea

• **Educational Background:**

Mar, 1988-Feb, 1994 Medical College, Catholic University of Korea

Mar. 1994-Feb. 1995 Internship in Our lady of Mercy Hospital, Catholic
University of Korea

Mar, 1996-Feb. 2000 Residency of Internal Medicine in Kangnam St. Mary's
Hospital, Catholic University of Korea

Sep, 1999-Aug. 2000 Master's degree, Graduate school of Medicine,
Catholic University of Korea

Mar. 2000-Feb, 2001 Clinical Fellow, Division of Hemato-oncology,
Catholic Hematopoietic stem cell transplantation center,
St. Mary's Hospital, Catholic University of Korea

Mar, 2004- Feb, 2007 Ph. D, Graduate school of Medicine,
Catholic University of Korea

• **Professional Experience:**

Mar. 2002- Mar, 2005 Instructor, Division of Hemato-oncology, Department of Internal Medicine,
Kangnam St. Mary's Hospital, Catholic University of Korea

Apr, 2005- Mar, 2009 Assistant Professor, Division of Hemato-oncology,
Kangnam St. Mary's Hospital, Catholic University of Korea

Jul, 2007-Dec, 2008 Research fellow, Cell & developmental biology
Weil Medical College of Cornell University, NY, USA

Apr, 2009- Mar, 2014 Associate Professor, Division of Hemato-oncology,
Seoul St. Mary's Hospital, Catholic University of Korea

Apr, 2014- at present Professor / Chief of Medical Oncology
Department of Internal Medicine, Seoul St. Mary's Hospital
Catholic University of Korea

• **Professional Organizations:**

Active member, The American Society of Clinical Oncology
Active member The American Association for Cancer Research
Active member, The European Society of Medical Oncology
Active member, The Korean Medical Association
Active member, The Korean Liver Cancer Association
The Korean Cancer Association, member of board director
The Korean Cancer Association, member of editorial board
The Korean Society of Medical Oncology, Director of Judging Committee
The Korean Society for Hospice and Palliative care, Director of Ethics
The Korean Society for Hospice and Palliative care, Editorial Committee
The Korean Cancer Study Group, Hepato-biliary-pancreatic cancer Committee
The Korean Cancer Study Group, Colorectal cancer Committee
The Korean Association IRB, information Committee
Health Insurance Review & Assessment Service, advisory Committee

• **Main Scientific Publications:**

- 1) β -Catenin expression is associated with cell invasiveness in pancreatic cancer. Korean J Intern Med 2019
- 2) Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2019
- 3) Impact of preoperative body compositions on survival following resection of biliary tract cancer. J Cachexia Sarcopenia Muscle 2019
- 4) Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Ann Oncol 2019
- 5) Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response. Asia Pac J Clin Oncol 2018
- 6) Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. Cancer Res Treat 2018

and over 100 since 2002